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ABSTRACT
Congenital adrenal hyperplasia (CAH) is a group of autosomal
recessive disorders, causing impaired secretion of cortisol and aldo-
sterone from the adrenal cortex, with subsequent overproduction of
adrenal androgens. The most common enzyme defect causing CAH is
steroid 21-hydroxylase deficiency. To determine the mutational spec-
trum in the Hungarian CAH population, the CYP21 active gene was
analyzed using PCR. A total of 297 Hungarian patients with 21-
hydroxylase deficiency are registered in the 2nd Department of Pe-
diatrics, Budapest, Hungary, and their clinical status was evaluated.
Blood samples for CYP21 genotype determination could be obtained
from 167 patients (representing 306 unrelated chromosomes and
56.2% of the total group of patients). Eight of the most common
mutations were screened [In2 (intron 2 splice mutation), I172N, Del
(Del: apparents large gene conversion), Q318X, R356W, 1761Tins,
ClusterE6, V281L] using allele-specific amplification. The most fre-
quent mutation in the Hungarian CAH population was found to be
In2. Our results have shown a good genotype/phenotype correlation
in case of most mutations; the In2 mutation is associated mostly with
the severe form of the disease, whereas I172N was expressed in a wide
spectrum of phenotypes. (J Clin Endocrinol Metab 84: 2369–2372,
1999)
CONGENITAL adrenal hyperplasia (CAH) encompassesa group of genetic disorders of adrenal steroidogen-
esis (1, 2) characterized by impaired activity of one of the
enzymes required for cortisol biosynthesis. Steroid-21-hy-
droxylase deficiency (21-OHD) is present in more than 95%
of the patients with CAH. The incidence of the severe forms
is 1 in 15,000 among Caucasians, whereas it seems to be
higher for mild forms (1:100 to 1:1000) (3, 4). Steroid 21-
hydroxylase normally converts 17-hydroxyprogesterone
into 11-deoxycortisol and progesterone into 11-deoxycorti-
costerone. These steroids are subsequently converted into
cortisol and aldosterone, respectively. Because of accumu-
lation of precursors of the cortisol pathway, 21-OHD causes
increased levels of androgens, affecting fetal sex differenti-
ation at an early stage (5).
CAH, resulting from 21-OHD, is a classical monogenic
disorder with a very wide range of disease manifestation.
This wide spectrum is characterized by severe classical
forms, with prenatal virilization with or without salt loss,
and milder nonclassical forms (NC) that may be asymptom-
atic or associated with symptoms of androgen excess devel-
oping during childhood or at puberty. Affected females
should be treated in utero, to reduce virilizing malformations
of external genitalia, but this treatment is controversial (6, 7).
Thus, prenatal diagnosis of 21-OHD is highly desired. Pa-
tients with CAH caused by 21-OHD have traditionally been
divided into three types: salt-wasting (SW); nonsalt losing or
simple virilizing (SV), and late-onset or NC forms. SW form
presents with neonatal electrolyte disturbances, together
with virilization of external genitalia, at birth in girls, and
sexual precocity (because puberty and gonadotropins are not
involved in boys). The SV form is similar but without elec-
trolyte disturbances. The NC form lacks the neonatal symp-
toms and presents with late-onset androgen excess ranging
from sexual precocity in childhood to menstrual distur-
bances, infertility, and hirsutism in adult women. This clin-
ical diversity is shown to result from different mutations in
the CYP21 gene, causing varying degrees of enzyme inacti-
vation. These mutations can be deletions, large gene con-
versions, or point mutations. The adrenal steroid 21-hydrox-
ylase enzyme (also called P450c21) is encoded by two genes:
CYP21 and CYP21P (8–10). These genes are located within
the human leukocyte antigen class III gene region on the
short arm of chromosome 6; both are 3.4-kb long and consist
of 10 exons. The CYP21P gene is a so-called pseudogene, with
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no evident function (11). The majority of the mutations in the
active steroid 21-hydroxylase gene originate from this highly
homologous adjacent pseudogene. The establishment of
genotyping of CYP21 gene has been especially challenging,
because of the complex structure of the locus.
There has not been any information available on the fre-
quencies of different types of mutations of the active CYP21
gene in the Hungarian population. It is possible that, as a
result of several centuries of intermingling foreign popula-
tions, the pattern of alterations of the CYP21 gene in Hungary
is different from the European pattern. The knowledge of
relative frequencies of the point mutations might be useful
to delineate appropriate strategies for prenatal diagnoses.
To analyze the mutational spectrum and genotype-phe-
notype correlation in Hungarian patients with 21-OHD, we
investigated the CYP21 gene for the most frequent
mutations.
Subjects and Methods
Patients
We analyzed the CYP21 active gene in 167 Hungarian patients (pa-
tients from 153 families, 14 sibling-pairs, 306 unrelated chromosomes)
with steroid 21-hydroxylase deficiency registered in the 2nd Department
of Pediatrics, Semmelweis University of Medicine. Clinical classification
was based on genital anomalies, the age at presentation, and the hor-
monal and electrolyte abnormalities.
DNA
Samples were extracted from peripheral blood leukocytes, as de-
scribed by Madisen (12). The eight most common mutations were an-
alyzed in the CYP21 gene: Del-apparent large gene conversion, I2 Splice,
Ile172Asn, Cluster E6, Leu307insT, Gln318Stop, Arg356Trp, and
Val281Leu.
PCR
Allele-specific PCR (ASA) was performed according to the protocol
described by Wedell et al.(13), with slight modifications. Initially, sam-
ples were analyzed for the presence of an active CYP21 gene, using an
allele-specific primer in exon 3. The samples containing the active gene
were further analyzed for the seven most frequent disease-causing,
known mutation sites amplifying CYP21 in two separate fragments, i.e.
downstream and upstream of the 8-bp deletion site in exon 3. In the first
round of PCR, the fragment was amplified; then, in the second round,
ASA was performed on the nonpseudogene sequence targeted at the
mutation sites. After initial denaturation at 96 C for 3 min, 30 cycles of
PCR were done at 96 C for 1 min, 54–56 C or 60 C (depending on the
primers used) for 30 sec, and 72 C for 3 min, in a reaction mixture
containing 10 mm Tris-HCl (pH 9.0 at room temperature), 1.5 mmol/L
MgCl2, 50 mmol/L KCl, 5% glycerol, 0.2 mmol/L deoxynucleotide
triphosphate, 1 U of Taq polymerase (Pharmacia Biotech, Uppsala,
Sweden), and 0.5 mmol/L of primers except the primer in limiting
concentration (0.15 mmol/L). The oligonucleotide primers were as de-
scribed by Wedell et al. (13) and synthesized by Pharmacia Biosystems.
We used 1% agarose gel electrophoresis (30 min, 12 V/cm) for separation
of PCR products, which were visualized by ethidium bromide staining.
Because of the nature of this method, deletions and apparent large
gene conversions were not distinguished from each other and are in-
cluded in the same group. In cases in which no evidence of deletions was
detected (we could not obtain samples from the parents of the patients),
the samples were designated, for example, In2/In2 (In2 being the intron
2 splice mutation) or Del. In other words, homozygosity could not be
distinguished from hemizygosity.
Results
The Hungarian CAH registry contains data on 297 patients
with 21-OHD, of which 268 individuals are living. Blood
samples could be obtained from 167 (62.3%) of the 268 living
patients, including 14 pairs of siblings, representing 153 fam-
ilies and 306 nonrelated chromosomes. Of the 167 patients,
101 (60.5%) were classified as suffering from the SW form,
another 45 (26.9%) suffered from the SV form, and only 21
(12.6%) of the index cases were considered to have the NC
form of 21-OHD (Table 1).
Because the sex ratio and clinical spectrum of 21-OHD in
the genotyped group were analogous to those in the whole
patient group, the total patient population seemed to be well
represented by the genotyped patients.
Screening for 8 mutations allows the identification of most
of the mutations in 282 (92.1%) out of 306 unrelated chro-
mosomes. Table 2 contains the distribution of different ge-
notypes and the relationships of genotype and phenotype in
the Hungarian 21-OHD patients. There are only 12 patients
(7%) whose mutations could not be characterized and 17
patients (10%) in whom only one mutated allele was char-
acterized. The most frequent genotypes are the In2/In2 or
Del (30.5%), the I172N/I172N or Del (10%), and the Del/Del
(9%).
In the SW form, the most frequent mutations were the In2
and the deletions. In the case of the SV form, the I172N
mutation comprised most of the defect; whereas, in the NC
form, the most frequent mutation was the V281L. In accor-
dance with the literature (14, 15), the In2 mutation in the
position of 659 (splice site mutation in intron 2) was found
to be the most frequent mutation. All patients in group 0,
predicted to have no enzyme activity, showed the most se-
vere form (SW). Patients with almost complete enzyme im-
pairment, carrying at least one allele with the In2 splicing
mutation (with the exception of alleles in category N), pre-
sented SW or SV forms. Clinical expression varied in cate-
gory B. Most of the patients carrying the I172N mutation had
the presumed SV form of the disease. At one end of the
phenotypic spectrum, there were evident salt wasters. At the
other end of the continuum, this group included two patients
with homo/hemizygous I172N mutation, presenting with
obvious NC 21-OHD. Half of the genotyped NC patients
carried the V281L (Group C) mutation.
TABLE 1. Number of patients with 21-hydroxylase deficiency in Hungary
Type gender
SW SV NC
Total
male female m 1 f male female m 1 f male female m 1 f
Registered 82 76 158 19 50 69 15 55 70 297
Alive 65 66 131 17 50 67 15 55 70 268
Dead 17 10 27 2 2 2 2 2 2 29
Genotyped 50 51 101 14 31 45 6 15 21 167
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Discussion
The aim of the study was to determine the genotype dis-
tribution of the Hungarian CAH patients with 21-OHD. Be-
cause of a high amount of ethnic mixing over the centuries
in the Hungarian population, it was not possible to assign our
patients as a homogenous ethnic group. This is the first
report of the Hungarian population-wide screening program
for CAH. Until now, this is the largest ongoing study de-
termining CAH patients’ genotypes with 21-OHD in Central-
Eastern Europe.
We screened 167 identified CAH patients in Hungary. This
number includes 62.3% of the living patients of the Hungar-
ian CAH registry. In this present work, we screened 7 of the
most common point mutations and deletion (in other words,
the absence of the active CYP21 gene) (16). Identifying these
mutations, we were able to determine 155 (92.8%) CAH ge-
notypes. However, 12 (7.2%) genotypes remained unknown.
This is not surprising if we consider that the 8 mutations that
we analyzed represent 90–92% of all mutations in the CYP21
gene, according to the literature (13, 16). To determine the
unknown genotypes, we are performing sequence analysis
on their CYP21 genes.
Genetic diagnosis is more complicated for steroid 21-hy-
droxylase deficiency than for many other monogenic disor-
ders, because of the high variability of the locus. If geno-
typing is performed without segregation of mutations in
families, the linkage phase of mutations in compound het-
erozygotes can be determined by allele-specific PCR, and the
positions of all pseudogene-derived mutations should be
analyzed (17). Our present study agrees with the previous
results of other nation-wide screening programs (13, 18–23).
In some other studies, variation has been detected, and
phenotypes are not always correlating with allelic variations
in CYP21 gene (24). For example, the In2 mutation manifests
with variable clinical symptoms (25, 26), whereas all of our
patients with In2 as the determining mutation, presented
with severe mineralocorticoid deficiency. On the other hand,
we found that patients with the I172N mutation revealed
clinical variation. This study agrees with the previous results
of Ja¨a¨skela¨inen et al. in 1997 (19). The I172N mutation is
known to result in clearly reduced enzymatic activity, to
about 1–2% of that found in the wild-type, and it is usually
associated with the SV form, although patients with the
I172N/deletion genotype with the SW form have been re-
TABLE 2. Genotype categories, exact genotypes, and variation in phenotype
Genotypes Group
Phenotypes
Total
SW SV NC
In2/In2 or Del A/A or A/0 44 7 2 51
I172N/I172N or Del B/B or B/0 1 14 2 17
Del/Del 0/0 15 2 2 15
nd/nd N/N 4 5 3 12
V281L/V281L or Del C/C or C/0 2 2 8 8
In2/I172N or In2 1 I172N/nd A/B or A/N 2 6 2 8
I172N/nd B/N 2 4 3 7
In2/nd A/N 3 3 2 6
R356W/R356W or Del 0/0 6 2 2 6
Q318X/Q318X or Del 0/0 5 2 2 5
1761Tins/1761 Tins or Del 0/0 4 2 2 4
V281L/nd C/N 1 2 1 2
I172N/V281L or I172N 1 V281L/nd B/C or B/N 2 1 1 2
V281L 1 Q318X/V281L 1 Q318X or Del 0/0 2 2 2 2
R356W/nd 0/N 2 2 2 2
I172N/R356W or I172N 1 R356W/nd B/0 or 0/N 1 1 2 2
1761Tins/Q318X or 1761Tins 1 Q318X/nd 0/0 or 0/N 1 1 2 2
In2/1761Tins or In2 1 1761Tins/nd A/0 or 0/N 2 2 2 2
I172N/Q318X or I172N 1 Q318X/nd B/0 or 0/N 1 2 2 1
In2 1 V281L/In2 1 V281L or Del A/A or A/0 1 2 2 1
In2 1 1761Tins/In2 0/A 1 2 2 1
In2 1 R356W/R356W 0/0 1 2 2 1
In2 1 V281L 1 1761Tins 1 R356W/In2 0/A 1 2 2 1
In2/1761Tins A/0 1 2 2 1
In2 1 I172N/I172N A/B 2 1 2 1
1761Tins 1 Q318X/Q318X 0/0 1 2 2 1
In2 1 I172N/In2 A/A 2 1 2 1
V281L 1 Q318X 1 R356W/Del 0/0 1 2 2 1
In2 1 I172N/In2 1 I172N or Del A/A or A/0 1 2 2 1
V281L/1761Tins or V281L 1 1761Tins/nd C/0 or 0/N 2 2 1 1
In2/V281L or In2 1 V281L/nd A/C or A/N 2 1 2 1
In2/ClusterE6 or In2 1 ClusterE6/nd A/0 or 0/N 1 2 2 1
Total 101 45 21 167
Enzyme activity: predicted degree of enzyme impairment on type of mutation:
0: 0% (Del, Q318X, R356W, 1761Tins, ClusterE6)
A: 0–1% (In2)
B: 2% (I172N)
C: 20–50% (V281L)
N: Not-determined enzyme impairment
nd: Not-determined genotype of the allele
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ported (27). In the present study, the severity of both (SW and
SV) mineralocorticoid deficiencies varied excessively; al-
though we formally cannot rule out some additional muta-
tions in CYP21 that might explain the observed clinical
heterogeneity.
Certain mutations in CYP21 cause a mild form of the
disease that is hard to distinguish from similar, common
conditions of unknown etiology. Thus, knowledge about the
molecular pathology of 21-OHD may provide a first step
toward the understanding of more complex hormonal dis-
orders. The use of PCR advances our knowledge of the mu-
tations causing SW, SV, and NC forms of CAH and is useful
in prenatal diagnosis of this disease.
In this study, we screened the entire accessible Hungarian
CAH population, using the ASA technique that was proven
to be effective for the rapid identification of the most com-
mon mutations in the CYP21 gene (13). However, the present
work brought our attention to the limits of this unique tech-
nique. Using the ASA method alone, we were not able to
determine the exact genotype of the patients without know-
ing the parents’ genotype. To eliminate this problem, we are
extending our screening program to the index patients’ fam-
ily, involving mothers and fathers. Having these data at
hand, we shall be able to determine the exact genotype-
phenotype correlation.
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